Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 19, 2019 - Issue 6
Submit an article Journal homepage
122
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC): can this lead to the adverse effect of hypogonadism?

Mehran AfsharDepartment of Oncology, St George's University Hospital NHS Foundation Trust, London, UKView further author information
,
Hiten R. H. PatelDepartment of Urology, University of Tromso, Tromso, NorwayView further author information
,
Ankit JainDepartment of Oncology, The Royal Wolverhampton NHS Trust, Wolverhampton, UKView further author information
,
Abhishek KumarDepartment of Statistics, Indira Gandhi Institute of Development Research, Mumbai, IndiaView further author information
,
Prashant PatelInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UKView further author information
,
Nicholas D. JamesInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK;The Cancer Centre, Queen Elizabeth Hospital Birmingham, Birmingham, UKView further author information
&
Emilio PorfiriThe Cancer Centre, Queen Elizabeth Hospital Birmingham, Birmingham, UKCorrespondence[email protected]
View further author information
 show all
Pages 529-532 | Received 21 Dec 2018, Accepted 16 Apr 2019, Published online: 02 May 2019

References

  • Milella M, Felici A. Biology of metastatic renal cell carcinoma. J Cancer. 2011;2:369–373.
  • Larkin JM, Pyle LM, Gore ME. Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies. Oncologist. 2010;15:1135–1146.
  • Donskov F, Michaelson MD, Puzanov I, et al. Comparative assessment of sunitinib-associated adverse events as potential biomarkers of efficacy in metastatic renal cell carcinoma (mRCC). Ann Oncol. 2012;23(Suppl.9):259. Abstract 785O.
  • Davis M, Figlin R, Hutson TE, et al. Asthenia and fatigue as potential biomarkers of sunitinib efficacy in metastatic renal cell carcinoma. Eur J Cancer. 2011;47:S135. 2011.ECCO16-ESMO36-ESTRO30 Abstract 1139.
  • Lodish MB, Stratakis CA. Endocrine side effects of broad-acting kinase inhibitors. Endocr Relat Cancer. 2010 Sep;17(3):233–244.
  • Lodish M. Kinase inhibitors: adverse effects related to the endocrine system. J Clin Endocrinol Metab. 2013 Apr;98(4):1333–1342.
  • Wolter P, Wildiers H, Vanderschueren D, et al. Hypogonadism in male patients treated with the tyrosine kinase inhibitors sunitinib or sorafenib. J Clin Oncol. 2009;27(Suppl.15s):3565. Abstract 356.
  • Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur J Endocrinol. 2008 Nov;159(5):507–514.
  • Motzer RJ, Hutson TE, McCann L, et al. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med. 2014 May 1;370(18):1769–1770.
  • Bianchi L, Rossi L, Tomao F, et al. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma. Endocr Relat Cancer. 2013 Aug 19;20(5):R233–R245.
  • Basciani S, Mariani S, Arizzi M, et al. Expression of platelet-derived growth factor-A (PDGF-A), PDGF-B, and PDGF receptor-alpha and -beta during human testicular development and disease. J Clin Endocrinol Metab. 2002;87:2310–2319.
  • Gambacorti-Passerini C, Tornaghi L, Cavagnini F, et al. Gynaecomastia in men with chronic myeloid leukaemia after imatinib. Lancet. 2003 Jun 7;361(9373):1954–1956.
  • Tauer JT, Ulmer A, Glauche I, et al. Long-term imatinib treatment does not cause testicular toxicity in male adolescents with chronic myeloid leukemia and in a juvenile rat model. Klin Padiatr. 2014;226(3):169–174.
  • Brassard M, Neraud B, Trabado S, et al. Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer. J Clin Endocrinol Metab. 2011 Sep;96(9):2741–2749.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.